February 2017

Merz Pharmaceuticals, SAFE to launch patient-centric spasticity initiative

Tuesday, February 28, 2017

Merz Pharmaceuticals has announced the launch of Life With Spasticity, an educational online platform intended to provide comprehensive information and motivational support for stroke survivors who experience post-stroke spasticity. Designed by and for individuals living with spasticity, the project is funded by Merz and has been developed in partnership with Stroke Alliance For Europe (SAFE).

[Read More]

My Life, Our Future opens genetic hemophilia repository to scientists

Tuesday, February 28, 2017

My Life, Our Future, a national program founded by the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ, opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments. 

[Read More]

PPD launches Rare Disease and Pediatric Center of Excellence

Tuesday, February 28, 2017

Pharmaceutical Product Development (PPD) has established a Rare Disease and Pediatric Center of Excellence to oversee all rare disease and pediatric-related drug development activities. This new center of excellence provides pharmaceutical and biotechnology clients with a dedicated team of professionals focused on the design and execution of clinical trials that address the unique strategic, operational, medical and scientific challenges of clinical studies in rare disease and pediatric patient populations.

[Read More]

PAREXEL International appoints Simon Harford as SVP & CFO

Tuesday, February 28, 2017

PAREXEL International, a global biopharmaceutical services provider, has announced the appointment of Simon Harford as senior vice president and chief financial officer effective June 1, 2017. He will serve on PAREXEL’s Business Review Committee, the company’s senior-most leadership team, and assist in developing and implementing PAREXEL’s strategic objectives. Harford will be based at the Company’s corporate headquarters in Waltham, Massachusetts.

[Read More]

Incyte, Abramson Cancer Center partner

Tuesday, February 28, 2017

Incyte has announced a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania. Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug discovery and development scientists to conduct collaborative research aimed at advancing the understanding of cancer biology and fostering innovative science in immunotherapy.

[Read More]

Scott Smith promoted to Celgene president and chief operating officer

Tuesday, February 28, 2017

Celgene has announced that president and chief operating officer (COO) Jacqualyn (Jackie) Fouse, Ph.D., has decided to retire from Celgene effective June 30, 2017. She will continue to serve as president and COO until April 1, and through June 30, she will serve as a strategic advisor to the management team. Jackie will not stand for reelection to the Celgene Board of Directors at the upcoming Annual Meeting in June. The company also announced the promotion of Scott Smith to President and COO, effective April 1, 2017, and the promotion of Terrie Curran to president, Global Inflammation & Immunology (I&I) Franchise, effective April 1, 2017.

[Read More]